BOSTON SCIENTIFIC CORPORATION REZUM; UNIT, ELECTROSURGICAL ENDOSCOPIC (WITH OR WITHOUT ACCESSORIES)
|
Back to Search Results |
|
Model Number D2201 |
Device Problem
Adverse Event Without Identified Device or Use Problem (2993)
|
Patient Problems
Inflammation (1932); Hematuria (2558); Erectile Dysfunction (4511)
|
Event Date 05/12/2021 |
Event Type
Injury
|
Event Description
|
It was reported that the patient presented with an international prostate symptom score (ipps) of 28, an international index of erectile function (iief) score of 4 and a prostate volume of 53 cm3.The patient is a chinese male with medical history of gastrointestinal and neurological disorders.The patient was enrolled into the clinical study.During the water vapor therapy procedure of the prostate, there were a total of three treatments delivered to the right lobe, four treatments to the left lobe and one treatment to the middle lobe.Three days following the index procedure, the patient was reported to be experiencing hematuria.The patient was discharged from the medical facility on tamsulosin hydrochloride sustained-release capsule (dose unknown).At 34 days post the index procedure, the patient experienced erectile dysfunction and an urinary volume assessment test completed at 36 days post the index procedure, found the urinary volume at 142 ml with peak flow rate of 11 ml/sec.152 days post the index procedure, the patient was diagnosed with prostatitis.The symptom of prostatitis was not considered to be resolved, and per the electronic data center (edc), there was no action taken to treat it.The investigator assessed the patient symptom of prostatitis as possible related to the procedure and device.
|
|
Manufacturer Narrative
|
Investigation summary: based on the information available, there was no device available for analysis and there was no report of a device performance allegation during treatment.The reported patient symptoms are known risks associated with water vapor therapy procedures and are noted as such in the device instructions for use.Device technical analysis: the device is not available for analysis; therefore, no physical or visual analysis of the product could be performed.Labeling review: the device instructions for use (ifu) was reviewed.The patient symptoms of hematuria and erectile dysfunction were found to be listed in the ifu.Investigation conclusion: based on the information available, a conclusion code of known inherent risk of device was assigned to this investigation.
|
|
Event Description
|
It was reported that the patient presented with an international prostate symptom score (ipps) of 28, an international index of erectile function (iief) score of 4 and a prostate volume of 53 cm3.The patient is a chinese male with medical history of gastrointestinal and neurological disorders.The patient was enrolled into the clinical study.During the water vapor therapy procedure of the prostate, there were a total of three treatments delivered to the right lobe, four treatments to the left lobe and one treatment to the middle lobe.Three days following the index procedure, the patient was reported to be experiencing hematuria.The patient was discharged from the medical facility on tamsulosin hydrochloride sustained-release capsule (dose unknown).At 34 days post the index procedure, the patient experienced erectile dysfunction and an urinary volume assessment test completed at 36 days post the index procedure, found the urinary volume at 142 ml with peak flow rate of 11 ml/sec.152 days post the index procedure, the patient was diagnosed with prostatitis.The symptom of prostatitis was not considered to be resolved, and per the electronic data center (edc), there was no action taken to treat it.The investigator assessed the patient symptom of prostatitis as possible related to the procedure and device.
|
|
Search Alerts/Recalls
|
|
|